Letter to the Editor
Use of biologics for pustulotic arthro-osteitis in two patients with palmoplantar pustulosis
Takenobu Ohashi,
Corresponding Author
Takenobu Ohashi
Department of Dermatology, Fukushima Medical University, Fukushima, Japan
Correspondence: Takenobu Ohashi, M.D., Ph.D., Department of Dermatology, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295, Japan. Email:
[email protected]Search for more papers by this author Yuko Suzuki,
Yuko Suzuki
Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan
Search for more papers by this author Toshiyuki Yamamoto,
Toshiyuki Yamamoto
Department of Dermatology, Fukushima Medical University, Fukushima, Japan
Search for more papers by this author
Takenobu Ohashi,
Corresponding Author
Takenobu Ohashi
Department of Dermatology, Fukushima Medical University, Fukushima, Japan
Correspondence: Takenobu Ohashi, M.D., Ph.D., Department of Dermatology, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295, Japan. Email:
[email protected]Search for more papers by this author Yuko Suzuki,
Yuko Suzuki
Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan
Search for more papers by this author Toshiyuki Yamamoto,
Toshiyuki Yamamoto
Department of Dermatology, Fukushima Medical University, Fukushima, Japan
Search for more papers by this author
First published: 10 May 2016
No abstract is available for this article.
References
- 1Morales-Múnera C, Vilarrasa E, Puig L. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol 2013; 168: 820–824.
- 2Bissonnette R, Nigen S, Langley RG et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomized controlled trial. J Eur Acad Dermatol Venereol 2014; 28: 1298–1305.
- 3Mohammad F, Vivekanandarajah A, Haddad H et al. Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature. BMJ Case Rep 2014; doi: 10.1136/bcr-2013-203318.
- 4Desai SB. Problems encountered during anti-tumour nercosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 757–790.
- 5Bessissow T, Renard M, Hoffman I et al. Non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther 2012; 36: 312–323.
